HIV-related cardiovascular disease and drug interactions

Kinjal A. Nanavati, Stacy D. Fisher, Tracie L Miller, Steven E Lipshultz

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

HIV infection is a global public health issue that is frequently associated with cardiovascular involvement. These HIV-associated cardiovascular manifestations are often clinically occult or attributed incorrectly to other non-cardiac disease processes. A heightened awareness and routine screening for cardiovascular involvement in HIV-infected patients leads to earlier detection and the hope for a reduction in associated morbidity and mortality. Left ventricular dysfunction, an independent predictor of mortality in HIV-infected patients, is the result of many causes in this population and may result in dilated cardiomyopathy and congestive heart failure in about 10% of patients. Other HIV-associated cardiovascular problems include infective endocarditis, cardiovascular malignancy, pulmonary arterial hypertension, vasculitis, pericardial effusion, premature atherosclerosis, and arrhythmias. HIV-associated cardiovascular emergencies include congestive heart failure, pulmonary edema, supraventricular and ventricular arrhythmias, endocarditis, and tamponade. Anti-infective and immunomodulatory therapies may be particularly helpful in this population to reduce associated cardiovascular disease. Highly active antiretroviral therapy may result in lipodystrophy, hyperlipidemia, truncal adiposity, and insulin resistance that can be improved by physical activity and training programs. Cardiovascular complications of therapeutic drugs in HIV-infected patients include torsade de pointes, congestive heart failure, dyslipidemia, accelerated atherosclerosis, and myocardial infarction. In summary, cardiovascular complications are important contributors to morbidity and mortality in HIV-infected patients that can be detected early in many cases and treated effectively.

Original languageEnglish
Pages (from-to)315-324
Number of pages10
JournalAmerican Journal of Cardiovascular Drugs
Volume4
Issue number5
DOIs
StatePublished - Nov 9 2004

Fingerprint

Cardiovascular Agents
Drug Interactions
Cardiovascular Diseases
HIV
Heart Failure
Endocarditis
Mortality
Cardiac Arrhythmias
Atherosclerosis
Hope
Morbidity
Lipodystrophy
Torsades de Pointes
Immunomodulation
Pericardial Effusion
Highly Active Antiretroviral Therapy
Adiposity
Dilated Cardiomyopathy
Left Ventricular Dysfunction
Pulmonary Edema

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

HIV-related cardiovascular disease and drug interactions. / Nanavati, Kinjal A.; Fisher, Stacy D.; Miller, Tracie L; Lipshultz, Steven E.

In: American Journal of Cardiovascular Drugs, Vol. 4, No. 5, 09.11.2004, p. 315-324.

Research output: Contribution to journalArticle

Nanavati, Kinjal A. ; Fisher, Stacy D. ; Miller, Tracie L ; Lipshultz, Steven E. / HIV-related cardiovascular disease and drug interactions. In: American Journal of Cardiovascular Drugs. 2004 ; Vol. 4, No. 5. pp. 315-324.
@article{1ba9779239fd4854892094184bc3c203,
title = "HIV-related cardiovascular disease and drug interactions",
abstract = "HIV infection is a global public health issue that is frequently associated with cardiovascular involvement. These HIV-associated cardiovascular manifestations are often clinically occult or attributed incorrectly to other non-cardiac disease processes. A heightened awareness and routine screening for cardiovascular involvement in HIV-infected patients leads to earlier detection and the hope for a reduction in associated morbidity and mortality. Left ventricular dysfunction, an independent predictor of mortality in HIV-infected patients, is the result of many causes in this population and may result in dilated cardiomyopathy and congestive heart failure in about 10{\%} of patients. Other HIV-associated cardiovascular problems include infective endocarditis, cardiovascular malignancy, pulmonary arterial hypertension, vasculitis, pericardial effusion, premature atherosclerosis, and arrhythmias. HIV-associated cardiovascular emergencies include congestive heart failure, pulmonary edema, supraventricular and ventricular arrhythmias, endocarditis, and tamponade. Anti-infective and immunomodulatory therapies may be particularly helpful in this population to reduce associated cardiovascular disease. Highly active antiretroviral therapy may result in lipodystrophy, hyperlipidemia, truncal adiposity, and insulin resistance that can be improved by physical activity and training programs. Cardiovascular complications of therapeutic drugs in HIV-infected patients include torsade de pointes, congestive heart failure, dyslipidemia, accelerated atherosclerosis, and myocardial infarction. In summary, cardiovascular complications are important contributors to morbidity and mortality in HIV-infected patients that can be detected early in many cases and treated effectively.",
author = "Nanavati, {Kinjal A.} and Fisher, {Stacy D.} and Miller, {Tracie L} and Lipshultz, {Steven E}",
year = "2004",
month = "11",
day = "9",
doi = "10.2165/00129784-200404050-00004",
language = "English",
volume = "4",
pages = "315--324",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - HIV-related cardiovascular disease and drug interactions

AU - Nanavati, Kinjal A.

AU - Fisher, Stacy D.

AU - Miller, Tracie L

AU - Lipshultz, Steven E

PY - 2004/11/9

Y1 - 2004/11/9

N2 - HIV infection is a global public health issue that is frequently associated with cardiovascular involvement. These HIV-associated cardiovascular manifestations are often clinically occult or attributed incorrectly to other non-cardiac disease processes. A heightened awareness and routine screening for cardiovascular involvement in HIV-infected patients leads to earlier detection and the hope for a reduction in associated morbidity and mortality. Left ventricular dysfunction, an independent predictor of mortality in HIV-infected patients, is the result of many causes in this population and may result in dilated cardiomyopathy and congestive heart failure in about 10% of patients. Other HIV-associated cardiovascular problems include infective endocarditis, cardiovascular malignancy, pulmonary arterial hypertension, vasculitis, pericardial effusion, premature atherosclerosis, and arrhythmias. HIV-associated cardiovascular emergencies include congestive heart failure, pulmonary edema, supraventricular and ventricular arrhythmias, endocarditis, and tamponade. Anti-infective and immunomodulatory therapies may be particularly helpful in this population to reduce associated cardiovascular disease. Highly active antiretroviral therapy may result in lipodystrophy, hyperlipidemia, truncal adiposity, and insulin resistance that can be improved by physical activity and training programs. Cardiovascular complications of therapeutic drugs in HIV-infected patients include torsade de pointes, congestive heart failure, dyslipidemia, accelerated atherosclerosis, and myocardial infarction. In summary, cardiovascular complications are important contributors to morbidity and mortality in HIV-infected patients that can be detected early in many cases and treated effectively.

AB - HIV infection is a global public health issue that is frequently associated with cardiovascular involvement. These HIV-associated cardiovascular manifestations are often clinically occult or attributed incorrectly to other non-cardiac disease processes. A heightened awareness and routine screening for cardiovascular involvement in HIV-infected patients leads to earlier detection and the hope for a reduction in associated morbidity and mortality. Left ventricular dysfunction, an independent predictor of mortality in HIV-infected patients, is the result of many causes in this population and may result in dilated cardiomyopathy and congestive heart failure in about 10% of patients. Other HIV-associated cardiovascular problems include infective endocarditis, cardiovascular malignancy, pulmonary arterial hypertension, vasculitis, pericardial effusion, premature atherosclerosis, and arrhythmias. HIV-associated cardiovascular emergencies include congestive heart failure, pulmonary edema, supraventricular and ventricular arrhythmias, endocarditis, and tamponade. Anti-infective and immunomodulatory therapies may be particularly helpful in this population to reduce associated cardiovascular disease. Highly active antiretroviral therapy may result in lipodystrophy, hyperlipidemia, truncal adiposity, and insulin resistance that can be improved by physical activity and training programs. Cardiovascular complications of therapeutic drugs in HIV-infected patients include torsade de pointes, congestive heart failure, dyslipidemia, accelerated atherosclerosis, and myocardial infarction. In summary, cardiovascular complications are important contributors to morbidity and mortality in HIV-infected patients that can be detected early in many cases and treated effectively.

UR - http://www.scopus.com/inward/record.url?scp=7244254466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7244254466&partnerID=8YFLogxK

U2 - 10.2165/00129784-200404050-00004

DO - 10.2165/00129784-200404050-00004

M3 - Article

C2 - 15449973

AN - SCOPUS:7244254466

VL - 4

SP - 315

EP - 324

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 5

ER -